Major depressive episodes over the course of 7 years and hippocampal subfield volumes at 7 tesla MRI: The PREDICT-MR study

2015 ◽  
Vol 175 ◽  
pp. 1-7 ◽  
Author(s):  
L.E.M. Wisse ◽  
G.J. Biessels ◽  
B.T. Stegenga ◽  
M. Kooistra ◽  
P.H. van der Veen ◽  
...  
Keyword(s):  
7 Tesla ◽  
Major Depressive ◽  
7 Tesla Mri ◽  
Major Depressive Episodes ◽  
Depressive Episodes ◽  
Mr Study

P1-271: MAJOR DEPRESSIVE EPISODES OVER THE COURSE OF 7 YEARS AND HIPPOCAMPAL VOLUMES AT 1.5 AND 7 TESLA MRI: THE PREDICT-MR STUDY

2014 ◽  
Vol 10 ◽  
pp. P409-P409
Author(s):  
Laura Wisse ◽  
Geert Jan Biessels ◽  
Minke Kooistra ◽  
Yolanda van der Graaf ◽  
Mirjam I. Geerlings
Keyword(s):  
7 Tesla ◽  
Major Depressive ◽  
7 Tesla Mri ◽  
Major Depressive Episodes ◽  
Depressive Episodes ◽  
Mr Study

What is the role of conventional antidepressants in the treatment of major depressive episodes with Mixed Features Specifier?

CNS Spectrums ◽  
2016 ◽  
Vol 22 (2) ◽  
pp. 120-125 ◽  
Author(s):  
Gianni L. Faedda ◽  
Ciro Marangoni
Keyword(s):  
Clinical Trials ◽  
Unipolar Depression ◽  
Preliminary Evidence ◽  
Major Depressive ◽  
Pharmacological Management ◽  
Diagnostic And Statistical Manual ◽  
Mixed Features ◽  
Effective Use ◽  
Major Depressive Episodes ◽  
Depressive Episodes

The newly introduced Mixed Features Specifier of Major Depressive Episode and Disorder (MDE/MDD) is especially challenging in terms of pharmacological management. Prior to the publication of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the symptoms of the mixed features specifier were intradepressive hypomanic symptoms, always and only associated with bipolar disorder (BD).Intradepressive hypomanic symptoms, mostly referred to as depressive mixed states (DMX), have been poorly characterized, and their treatment offers significant challenges. To understand the diagnostic context of DMX, we trace the nosological changes and collocation of intradepressive hypomanic symptoms, and examine diagnostic and prognostic implications of such mixed features.One of the reasons so little is known about the treatment of DMX is that depressed patients with rapid cycling, substance abuse disorder, and suicidal ideation/attempts are routinely excluded from clinical trials of antidepressants. The exclusion of DMX patients from clinical trials has prevented an assessment of the safety and tolerability of short- and long-term use of antidepressants. Therefore, the generalization of data obtained in clinical trials for unipolar depression to patients with intradepressive hypomanic features is inappropriate and methodologically flawed.A selective review of the literature shows that antidepressants alone have limited efficacy in DMX, but they have the potential to induce, maintain, or worsen mixed features during depressive episodes in BD. On the other hand, preliminary evidence supports the effective use of some atypical antipsychotics in the treatment of DMX.

Sign in / Sign up

Export Citation Format

Share Document